Data / Drug companies / Recordati Rare Diseases, Inc.
Recordati Rare Diseases, Inc.: 17 products in the FDA NDC directory, labeler code 55292
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Recordati Rare Diseases, Inc. (labeler code 55292) lists 17 products in the FDA National Drug Code Directory, covering 7 finished drugs by generic name. By type: 17 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on February 4, 2022.
The request: Watch Recordati Rare Diseases, Inc. (FDA labeler code 55292): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 55292
- Products in commercial distribution
- 17
- Packages
- 21
- Finished drugs by generic name
- 7
- Prescription products
- 17
- Over the counter products
- 0
- Flagged as original packager
- 17 of 17 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 2
- Earliest marketing start
- July 20, 1983
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 15 | 88.2% |
| Biologics (BLA) | 2 | 11.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 17 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Pasireotide | 8 | 1 |
| Osilodrostat | 4 | 1 |
| Hemin | 1 | 1 |
| Sutimlimab-jome | 1 | 1 |
| Cysteamine hydrochloride | 1 | 2 |
| Succimer | 1 | 2 |
| Ibuprofen lysine | 1 | 3 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Kit | 5 | 29.4% |
| Tablet, coated | 4 | 23.5% |
| Injection | 3 | 17.6% |
| Solution | 2 | 11.8% |
| Powder, for solution | 1 | 5.9% |
| Injection, solution, concentrate | 1 | 5.9% |
| Capsule | 1 | 5.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Cortisol Synthesis Inhibitor | 4 |
| Somatostatin Analog | 3 |
| Classical Complement Pathway Inhibitor | 1 |
| Cystine Depleting Agent | 1 |
| Lead Chelator | 1 |
| Nonsteroidal Anti-inflammatory Drug | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Enjaymo | 55292-820 | Injection, solution, concentrate | Biologics (BLA) | February 4, 2022 |
| Cystadrops | 55292-410 | Solution | New drug applications (NDA) | August 19, 2020 |
| Isturisa | 55292-331 | Tablet, coated | New drug applications (NDA) | March 31, 2020 |
| Isturisa | 55292-330 | Tablet, coated | New drug applications (NDA) | March 31, 2020 |
| Isturisa | 55292-321 | Tablet, coated | New drug applications (NDA) | March 31, 2020 |
| Isturisa | 55292-320 | Tablet, coated | New drug applications (NDA) | March 31, 2020 |
| Signifor LAR | 55292-143 | Kit | New drug applications (NDA) | December 15, 2014 |
| Signifor LAR | 55292-142 | Kit | New drug applications (NDA) | December 15, 2014 |
| Signifor LAR | 55292-141 | Kit | New drug applications (NDA) | December 15, 2014 |
| Signifor LAR | 55292-140 | Kit | New drug applications (NDA) | December 15, 2014 |
| Signifor LAR | 55292-139 | Kit | New drug applications (NDA) | December 15, 2014 |
| Chemet | 55292-201 | Capsule | New drug applications (NDA) | August 21, 2013 |
| Signifor | 55292-133 | Injection | New drug applications (NDA) | December 14, 2012 |
| Signifor | 55292-132 | Injection | New drug applications (NDA) | December 14, 2012 |
| Signifor | 55292-131 | Injection | New drug applications (NDA) | December 14, 2012 |
| Neoprofen | 55292-122 | Solution | New drug applications (NDA) | April 13, 2006 |
| Panhematin | 55292-702 | Powder, for solution | Biologics (BLA) | July 20, 1983 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.